Company intelligence / Profile preview
Astraea Therapeutics
- Ownership
- Private
- Development stage
- Phase 1
Overview
Astraea Therapeutics has advanced its lead candidate(s) into Phase I clinical trials for smoking cessation. Preclinical data support efficacy in preventing relapse triggered by stress or cues and suggest potential application across multiple substance addictions. Additional programs are at the preclinical stage targeting pain management without typical opioid side effects and alcohol use disorder.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesSynthetic peptides
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Astraea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Astraea Therapeutics.